“Food allergies can have a significant impact on the lives of children and adults, and they are a growing public health concern for which there are currently no FDA-approved treatments,” said M.D., chief medical officer and head of Global Product Development. He said, “We are committed to helping address this high unmet medical need and look forward to working with leaders in the field to further develop Omalizumab as a potential medicine to help people with this condition that can be life-threatening.” Food allergies can be life-threatening, and result in an estimated 200,000 emergency room visits each year. Up to 8 percent of children and 4 percent of adults in the U.S.
are affected by food allergies, and the incidence is increasing. Breakthrough therapy designation was granted on the basis of data from seven clinical studies over the last decade assessing the efficacy and safety of…
